RECRUITING

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Conditions

Chronic Kidney Disease(CKD)Type 1 Diabetes (T1D)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Official Title

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Quick Facts

Study Start:2025-03-01

Study Completion:2026-07-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06694558

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. T1D CKD subjects: 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2) 4. Diagnosed with albuminuria (UACR 30-500 mg/g) 5. On insulin injections or pump 6. On CGM 2. Controls: T1D subjects without CKD 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. No CKD (eGFR \>90 ml/min/1.73 m2) 4. No albuminuria (UACR \<30 mg/g) 5. On insulin injections or pump 6. On CGM	1. Hemoglobin \<9 2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days 3. pregnancy or plans to become pregnant 4. On steroids 5. Diagnosed with cancer, immunosuppression/autoimmune conditions 6. Reported heavy alcohol use or recreational drug use 7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion

Inclusion Criteria

Exclusion Criteria

1. T1D CKD subjects:
1. Adults, males or females diagnosed with T1D
2. Age 18-65 years
3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
4. Diagnosed with albuminuria (UACR 30-500 mg/g)
5. On insulin injections or pump
6. On CGM
2. Controls: T1D subjects without CKD
1. Adults, males or females diagnosed with T1D
2. Age 18-65 years
3. No CKD (eGFR \>90 ml/min/1.73 m2)
4. No albuminuria (UACR \<30 mg/g)
5. On insulin injections or pump
6. On CGM

1. Hemoglobin \<9
2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days
3. pregnancy or plans to become pregnant
4. On steroids
5. Diagnosed with cancer, immunosuppression/autoimmune conditions
6. Reported heavy alcohol use or recreational drug use
7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion

Contacts and Locations

Study Contact

Andrea Debs

CONTACT

216-445-8354

debsa@ccf.org

Principal Investigator

Rong M Zhang, MD

PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Study Locations (Sites)

Cleveland Clinic

Cleveland, Ohio, 44195

United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

Rong M Zhang, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-01

Study Completion Date2026-07-01

Study Record Updates

Study Start Date2025-03-01

Study Completion Date2026-07-01

Terms related to this study

Additional Relevant MeSH Terms

Chronic Kidney Disease(CKD)
Type 1 Diabetes (T1D)